Ptc Therapeutics (PTCT) EBT (2012 - 2026)

Ptc Therapeutics' EBT history runs 15 years deep, the most recent figure standing at $97.5 million for Q2 2026.

• In Q2 2026, EBT rose 237.29% year-over-year to $97.5 million; the TTM figure through Jun 2026 stood at $486.1 million (up 12.95% YoY), while the FY2025 annual figure was $1.2 billion, up 308.72% from the prior year.
• EBT for Q2 2026 stood at $97.5 million, up from -$2.5 million in the prior quarter.
• The five-year high for EBT was $929.8 million in Q1 2025, with the low at -$330.4 million in Q4 2024.
• The 5-year median for EBT is -$109.9 million (2022), against an average of -$35.0 million.
• The sharpest annual moves came in 2025 and 2026: EBT jumped 1197.84% in 2025, then tumbled 100.26% in 2026.
• Ptc Therapeutics' EBT stood at -$193.3 million in 2022, then decreased by 27.08% to -$245.7 million in 2023, then slumped by 34.48% to -$330.4 million in 2024, then soared by 225.34% to $414.1 million in 2025, then plunged by 76.44% to $97.5 million in 2026.
• Business Quant data shows PTCT's EBT at $97.5 million in Q2 2026, -$2.5 million in Q1 2026, and $414.1 million in Q4 2025.